Peptide news
A curated feed of regulatory, scientific, industry and cultural developments. Each item links out to its original source — we summarise, we don’t republish.
- Science
Ageing researcher ranks fasting above exercise and NR in a 12-week trial
Prof Morten Scheibye-Knudsen (University of Copenhagen) describes seven interventions he uses himself, and reports a 12-week trial in 80 adults aged 65+ comparing nicotinamide riboside, intermittent fasting and exercise. He states the trial is not yet peer-reviewed or published.
- Regulatory
Panel backs Semax and Epitalon but rejects DSIP on day two
The Pharmacy Compounding Advisory Committee recommended Semax (8-5) and Epitalon (7-4) for the Section 503A bulks list, but voted 6-7 against emideltide — the FDA's designation for DSIP — making it the only one of the seven peptides reviewed to be turned down.
- Regulatory
FDA advisory panel votes to allow compounding of BPC-157, KPV, TB-500 and MOTS-c
On day one of a two-day meeting the Pharmacy Compounding Advisory Committee narrowly recommended adding four peptides to the Section 503A bulk drug substances list — BPC-157, KPV and TB-500 each 8-6 with one abstention, and MOTS-c 7-5 with two abstentions. The votes are advisory and non-binding.
- Science
Advisory committee sided with peptides over the FDA's own reviewers
TIME reports that the committee's favourable votes ran against the FDA review team's assessment, which found only one small trial for BPC-157 and no human studies for KPV, and notes that several voting members had ties to companies positioned to benefit.
- Regulatory
FDA advisory committee to review BPC-157, KPV, TB-500 and MOTS-c
Meeting preview: ahead of the vote, the FDA's Pharmacy Compounding Advisory Committee was set to weigh whether several popular peptides should be available through compounding pharmacies.
- Culture
Why 'anti-aging' peptide shots are trending
A feature on the social-media-driven popularity of anti-aging peptide injections among celebrities — and what the science actually shows.
- Regulatory
BPC-157 removed from the FDA's restricted Category 2 list
BPC-157 entered a 'transitional' state — no longer barred from compounding, but still not an FDA-approved drug, pending a bulk-substances review.
- Regulatory
Wellness world eager for RFK Jr.'s move on peptides
Reporting on the policy push to widen consumer access to injectable peptides through compounding pharmacies, and the safety debate around it.
- Science
The Peptide Craze
Cardiologist Eric Topol examines the surge of interest in peptides and what the underlying evidence does and doesn't support.
- Regulatory
RFK Jr. signals ~14 peptides moving toward Category 1
Speaking on the Joe Rogan Experience, the HHS Secretary said he expected the FDA to reclassify about 14 injectable peptides to widen access from 'ethical suppliers'.
- Science
Influencers are promoting peptides — what does the science say?
A look at the gap between online enthusiasm for muscle-growth and longevity peptides and the thin state of human clinical evidence.
- Science
A closer look at unapproved peptide injections promoted by influencers
Coverage of the rise of unapproved peptide injections marketed by influencers and celebrities, and the regulatory questions they raise.
- Culture
Derrick Lewis says the UFC 'provided me with some great peptides'
The UFC heavyweight's comments drew a clarification from the promotion, which says it does not supply banned peptides.
- Industry
Peptide therapeutics market forecast for 2026
Market analysts project continued double-digit growth for the broad peptide-therapeutics category, though estimates vary widely by methodology.
- Science
The trend of unproven peptides spreading through influencers
An examination of how unregulated peptides have spread through wellness and fitness influencer culture.
- Regulatory
FDA removes five peptides from Category 2
An earlier loosening: AOD-9604, CJC-1295, Ipamorelin acetate, Thymosin Alpha-1 and Selank acetate were removed from the restricted compounding list (still not approved drugs).
16 items · summaries are neutral and link to the original reporting.